Introduction: Lupus nephritis (LN) is common and carries a high burden of morbidity in SLE patients. The adipokine ‘‘visfatin’’is highly expressed in visceral fat, exerts several pro inflammatory functions and was demonstrated as a marker of endothelial dysfunction (ED) in chronic kidney disease (CKD). Aim of the work: to evaluate the state of serum visfatin in SLE patients and to detect its possible correlation to disease activity and kidney affection. Also, to define a possible correlation between the level of visfatin before and after a treatment regimen of combined mycophenolate mofetil and corticosteroids. Patients and methods: visfatin was assayed using enzyme-linked immunosorbent assay (ELISA), chemical and immunological markers of SLE and LN were measured in 50 SLE patients (included 25 patients with LN and 25 patients without LN), and compared with 25 age and sex matched healthy controls. Disease activity was assessed using SLE Disease Activity Index (SLEDAI). Renal biopsies were taken from LN subgroup and were classified according to the modified WHO classification. [1] Results: There was statistically highly significant difference (P < 0.001) as regards serum visfatin between patients (mean 8.31 ± 3.60, median 8, 64), and controls (mean 4.60 ± 2.01), serum visfatin showed significantly higher levels in LN compared to the non-lupus nephritis group (mean 8.78 ± 3.81 ng/ml,) versus (mean 7.85 ± 3.38 ng/ml,). Also, visfatin level was significantly higher among the active (mean 9.30 ± 3.14,) compared to the inactive group (mean 4.37 ± 2.46). Visfatin had a highly significant positive correlation with SLEDAI, disease duration, corticosteroids treatment duration, ESR and CRP. Also, a significant inverse correlation existed between visfatin, WBCs and Platelets count, correlation studies between visfatin level and low level of C3, C4 were significant. The correlation between serum visfatin level and Carotid artery intima media thickness by carotid Doppler imaging was also significant. There was a significant decrease (P= 0.041) between pre-treatment visfatin level and post treatment level after 3 months of MMF and high dose CS treatment, Visfatin mean decreased from (8.78 ± 3.81 ng/ml) to (8.29 ± 3.44 ng/ml). Conclusion: visfatin is closely associated with SLE activity especially with lupus nephritis revealing the promising role of this adipokine in SLE activity measurement and prediction of renal involvement in SLE patients.
| Published in |
American Journal of Internal Medicine (Volume 4, Issue 2-1)
This article belongs to the Special Issue Different Medical Research From Middle East |
| DOI | 10.11648/j.ajim.s.2016040201.14 |
| Page(s) | 18-23 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2016. Published by Science Publishing Group |
Systemic Lupus Erythematosus, Lupus Nephritis, Nicotinamide Phosphoribosyl Transferase/Visfatin
| [1] | Pons-Estel GJ, Alarćon GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010; 39: 257-68. |
| [2] | Singh S, Saxena R. Lupus nephritis. Am J Med Sci. 2009; 337: 451–60. |
| [3] | Fain, J. N., A. K. Madan, M. L. Hiler, P. Cheema, and S. W. Bahouth. 2004. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145: 2273–82. |
| [4] | Fukuhara, A., M. Matsuda, M. Nishizawa, K. Segawa, M. Tanaka, K. Kishimoto, Y. Matsuki, M. Murakami, T. Ichisaka, H. Murakami, et al. 2005. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307: 426–30. |
| [5] | A. R. Moschen, A. Kaser, B. Enrich, B. Mosheimer, M. Theurl, H. Niederegger, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties J Immunol, 178 (3) (2007), pp. 1748–58. |
| [6] | Y. Masui, Y. Asano, S. Shibata, S. Noda, K. Akamata, N. Aozasa, et al. A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response Rheumatology (Oxford), 52 (7) (2013), pp. 1239–44. |
| [7] | N. Fouda, N. Abaza, R. El-Hilaly, H.W. El Said, R.H. EL-kabarity Evaluation of visfatin in patients with systemic lupus erythematosus: correlation with disease activity and lupus nephritis Egypt Rheumatologist, 34 (1) (2012), pp. 9–17. |
| [8] | Allison AC, Eugui EM: Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000, 47: 85-118. |
| [9] | Appel GB, Contreras G, Dooley MA: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009, 20: 1103-16. |
| [10] | Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 2006; 40: 1725. |
| [11] | Chan, D. C., Watts, G. F., Barrett, P. H., Burke, V. (2003) Waist circumference, waist-to-hip ratio and body mass index as predictors of adipose tissue compartments in men. QJM 96: 441–447. |
| [12] | Griffiths, B., Mosca, M. & Gordon, C. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best practice & research. Clinical rheumatology 19: 2005; 685-708. |
| [13] | Burkhardt H, Bojarsky G, Gretz N, Gladisch R. Creatinine clearance, Cockcroft-Gault formula and cystatin C: Estimators of true glomerular filtration rate in the elderly? Gerontology 48: 2002; 140–6. |
| [14] | M. Ozgen, S.S. Koca, K. Aksoy, N. Dagli, B. Ustundag, A. Isik. Visfatin levels and intima-media thicknesses in rheumatic diseases. Clin Rheumatol, 30 (6) (2011), pp. 757–63.16. Kiriakidou M, Cotton D, Taichman D, Williams S. Systemic lupus erythematosus. Ann Intern Med 2013; 159: ITC4-1. |
| [15] | Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, et al. International Society of Nephrology Working Group on the Classification of Lupus Nephritis, Renal Pathology Society Working Group on the Classification of Lupus Nephritis. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004; 65: 521–30. |
| [16] | Kiriakidou M, Cotton D, Taichman D, Williams S. Systemic lupus erythematosus. Ann Intern Med 2013; 159: ITC4-1. |
| [17] | Appel GB, Radhakrishnan J, D’Agati V: Secondary glomerular disease. In The Kidney. Edited by Brenner BM. 8th edition. Philadelphia, PA: Saunders; 2007: 1067-148. |
| [18] | Krysiak R, Handzlik-Orlik G, Okopien B. The role of adipokines in connective tissue diseases. Eur J Nutr 2012; 51: 513-28. |
| [19] | C. P. Chung, A. G. Long, J.F. Solus, Y.H. Rho, A. Oeser, P. Raggi, et al. Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis Lupus, 18 (9) (2009), pp. 799–806. |
| [20] | J. B. De Sanctis, M. Zabaleta, N.E. Bianco, J.V. Garmendia, L. Rivas Serum adipokine levels in patients with systemic lupus erythematosus Autoimmunity, 42 (4) (2009), pp. 272–4. |
| [21] | Y. S. Kang, H. K. Song, M. H. Lee, G. J. Ko, J. Y. Han, S. Y. Han, et al. Visfatin is upregulated in type-2 diabetic rats and targets renal cell Kidney Int, 78 (2010), pp. 170–81. |
| [22] | Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant. 2008; 23: 959-65. |
| [23] | Axelsson, A. Witasp, J.J. Carrero, A.R. Qureshi, M.E. Suliman, O. Heimbürger, et al. Circulating J. levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD Am J Kidney Dis, 49 (2) (2007), pp. 237–44. |
| [24] | P. Ochodnicky, S. Vettoretti, R.H. Henning, H. Buikema, R.P. Van Dokkum, D. de Zeeuw. Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response J Nephrol, 19 (3) (2006), pp. 246–58. |
| [25] | F. Brentano, O. Schorr, C. Ospelt, J. Stanczyk, R.E. Gay, S. Gay, et al. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum, 56 (9) (2007), pp. 2829–39. |
| [26] | K. Oki, K. Yamane, N. Kamei, H. Nojima, N. Kohno.Circulating visfatin level is correlated with inflammation, but not with insulin resistance Clin Endocrinol (Oxf)., 67 (5) (2007), pp. 796–800. |
| [27] | S. S. Bessa, S. M. Hamdy, R. G. El-Sheikh. Serum visfatin as a non-traditional biomarker of endothelial dysfunction in chronic kidney disease: an Egyptian studyEur J Intern Med, 21 (6) (2010), pp. 530–5. |
| [28] | N. Busso, M. Karababa, M. Nobile et al., “Pharmacological inhibition of nicotinamide phosphoribosyltransferase/ visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD,” PLoS ONE, vol. 3, no. 5, Article ID e2267, 2008. |
| [29] | Crispín JC, Oukka M, Bayliss G, et al. Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys. J Immunol 2008; 181: 8761-6. |
| [30] | A. Stofkova. Resisitin and visfatin: Regulators of insulin sensitivity, inflammation and immunity. Endocrine Regulations, 44 (2010), pp. 25–36. |
| [31] | R. Gómez, J. Conde, M. Scotece, J.J. Gómez-Reino, F. Lago, O. Gualillo. What’s new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol, 7 (9) (2011), pp. 528–36. |
| [32] | Moschen AR, Geiger S, Gerner R, Tilg H. Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammationrelated bone disease. Mutat Res 2010; 690(1–2): 95–101. |
| [33] | Sommer G., Garten, A., Petzold, S., Beck-Sickinger, A.G., Bluher, M., Stumvoll, M., et al. (2008) Visfatin/PBEF/Nampt: Structure, Regulation and Potential Function of a Novel Adipokine. Clinical Science, 115, 13-23. |
| [34] | N Hussain, G Jaffery, S Hasnain. Serum Complement C3 and C4 Levels in Relation to Diagnosis of Lupus Nephritis. Tropical Journal of Pharmaceutical Research, December 2008; 7 (4): 1117-21. |
| [35] | Chan TM, Li FK, Tang CSO, Wong RWS, Fang GX, et al. Effi cacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000, 343: 1156-62. |
| [36] | Ginzler EM, Dooley MA, Aranow C: Mycophenolate mofetil or IV cyclophosphamide for lupus nephritis. N Engl J Med 2005, 353: 2219-28. |
APA Style
Eman. H. El Sayed, Mohamed S. Brakat, Wael M. Diab, Mona H. Abd Elmaged, Manal. Y. Tayel, et al. (2016). Study of the Role of Nicotinamide Phosphoribosyl Transferase/Visfatin in Egyptian Patients with Systemic Lupus Erythematous and Lupus Nephritis. American Journal of Internal Medicine, 4(2-1), 18-23. https://doi.org/10.11648/j.ajim.s.2016040201.14
ACS Style
Eman. H. El Sayed; Mohamed S. Brakat; Wael M. Diab; Mona H. Abd Elmaged; Manal. Y. Tayel, et al. Study of the Role of Nicotinamide Phosphoribosyl Transferase/Visfatin in Egyptian Patients with Systemic Lupus Erythematous and Lupus Nephritis. Am. J. Intern. Med. 2016, 4(2-1), 18-23. doi: 10.11648/j.ajim.s.2016040201.14
AMA Style
Eman. H. El Sayed, Mohamed S. Brakat, Wael M. Diab, Mona H. Abd Elmaged, Manal. Y. Tayel, et al. Study of the Role of Nicotinamide Phosphoribosyl Transferase/Visfatin in Egyptian Patients with Systemic Lupus Erythematous and Lupus Nephritis. Am J Intern Med. 2016;4(2-1):18-23. doi: 10.11648/j.ajim.s.2016040201.14
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajim.s.2016040201.14,
author = {Eman. H. El Sayed and Mohamed S. Brakat and Wael M. Diab and Mona H. Abd Elmaged and Manal. Y. Tayel and Ragaa. A. Ramadan},
title = {Study of the Role of Nicotinamide Phosphoribosyl Transferase/Visfatin in Egyptian Patients with Systemic Lupus Erythematous and Lupus Nephritis},
journal = {American Journal of Internal Medicine},
volume = {4},
number = {2-1},
pages = {18-23},
doi = {10.11648/j.ajim.s.2016040201.14},
url = {https://doi.org/10.11648/j.ajim.s.2016040201.14},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.s.2016040201.14},
abstract = {Introduction: Lupus nephritis (LN) is common and carries a high burden of morbidity in SLE patients. The adipokine ‘‘visfatin’’is highly expressed in visceral fat, exerts several pro inflammatory functions and was demonstrated as a marker of endothelial dysfunction (ED) in chronic kidney disease (CKD). Aim of the work: to evaluate the state of serum visfatin in SLE patients and to detect its possible correlation to disease activity and kidney affection. Also, to define a possible correlation between the level of visfatin before and after a treatment regimen of combined mycophenolate mofetil and corticosteroids. Patients and methods: visfatin was assayed using enzyme-linked immunosorbent assay (ELISA), chemical and immunological markers of SLE and LN were measured in 50 SLE patients (included 25 patients with LN and 25 patients without LN), and compared with 25 age and sex matched healthy controls. Disease activity was assessed using SLE Disease Activity Index (SLEDAI). Renal biopsies were taken from LN subgroup and were classified according to the modified WHO classification. [1] Results: There was statistically highly significant difference (P Conclusion: visfatin is closely associated with SLE activity especially with lupus nephritis revealing the promising role of this adipokine in SLE activity measurement and prediction of renal involvement in SLE patients.},
year = {2016}
}
TY - JOUR T1 - Study of the Role of Nicotinamide Phosphoribosyl Transferase/Visfatin in Egyptian Patients with Systemic Lupus Erythematous and Lupus Nephritis AU - Eman. H. El Sayed AU - Mohamed S. Brakat AU - Wael M. Diab AU - Mona H. Abd Elmaged AU - Manal. Y. Tayel AU - Ragaa. A. Ramadan Y1 - 2016/02/29 PY - 2016 N1 - https://doi.org/10.11648/j.ajim.s.2016040201.14 DO - 10.11648/j.ajim.s.2016040201.14 T2 - American Journal of Internal Medicine JF - American Journal of Internal Medicine JO - American Journal of Internal Medicine SP - 18 EP - 23 PB - Science Publishing Group SN - 2330-4324 UR - https://doi.org/10.11648/j.ajim.s.2016040201.14 AB - Introduction: Lupus nephritis (LN) is common and carries a high burden of morbidity in SLE patients. The adipokine ‘‘visfatin’’is highly expressed in visceral fat, exerts several pro inflammatory functions and was demonstrated as a marker of endothelial dysfunction (ED) in chronic kidney disease (CKD). Aim of the work: to evaluate the state of serum visfatin in SLE patients and to detect its possible correlation to disease activity and kidney affection. Also, to define a possible correlation between the level of visfatin before and after a treatment regimen of combined mycophenolate mofetil and corticosteroids. Patients and methods: visfatin was assayed using enzyme-linked immunosorbent assay (ELISA), chemical and immunological markers of SLE and LN were measured in 50 SLE patients (included 25 patients with LN and 25 patients without LN), and compared with 25 age and sex matched healthy controls. Disease activity was assessed using SLE Disease Activity Index (SLEDAI). Renal biopsies were taken from LN subgroup and were classified according to the modified WHO classification. [1] Results: There was statistically highly significant difference (P Conclusion: visfatin is closely associated with SLE activity especially with lupus nephritis revealing the promising role of this adipokine in SLE activity measurement and prediction of renal involvement in SLE patients. VL - 4 IS - 2-1 ER -
Email: